-
公开(公告)号：US10941182B2
公开(公告)日：2021-03-09
申请号：US15317911
申请日：2015-06-10
Applicant: AMGEN INC.
Inventor： Jerry Ryan Holder , Gayathri Swaminath , Michael J. Frohn , Brian Alan Lanman , Anthony B. Reed , Leslie P. Miranda , John G. Allen , Alexander J. Pickrell , Aaron C. Siegmund , Lewis D. Pennington , Bryant Yang
Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.
-
公开(公告)号：US20250059179A1
公开(公告)日：2025-02-20
申请号：US18696948
申请日：2022-04-28
Applicant: AMGEN INC.
Inventor： Brian Alan Lanman , Ryan Paul Wurz , Wei Zhao , Xiaofen Li , Michael M. Yamano , Yunxiao Li , Ning Chen , Sebastian Leth-Petersen , Kexue Li , Liping Pettus , Rene Rahimoff , Primali Vasundera Navaratne , Huan Rui
IPC: C07D417/14 , A61K31/517 , A61K31/5377 , A61K31/5383 , A61K31/5386 , A61K31/541 , A61K31/55 , A61K31/551 , C07D471/04 , C07D471/08 , C07D487/04 , C07D487/10 , C07D487/20 , C07D498/04 , C07D498/10 , C07D519/00
Abstract: The present disclosure provides compounds useful for the inhibition of KRAS G12D. The compounds have a general Formula I: (I) wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, cancer.
-
公开(公告)号：US11807693B2
公开(公告)日：2023-11-07
申请号：US17160819
申请日：2021-01-28
Applicant: AMGEN INC.
Inventor： Jerry Ryan Holder , Gayathri Swaminath , Michael J. Frohn , Brian Alan Lanman , Anthony B. Reed , Leslie P. Miranda , John Gordon Allen , Alexander J. Pickrell , Aaron C. Siegmund , Lewis D. Pennington , Bryant Yang
CPC classification number: C07K7/08 , A61K38/10 , A61K47/542 , A61K47/60 , C07K14/47 , A61K38/00 , C07K2319/30
Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.
-
公开(公告)号：US11096939B2
公开(公告)日：2021-08-24
申请号：US16428163
申请日：2019-05-31
Applicant: Amgen Inc.
Inventor： Shon Booker , John Gordon Allen , Brian Alan Lanman , Ryan Paul Wurz , Ning Chen , Victor J. Cee , Patricia Lopez , Aaron C. Siegmund , Michael D. Bartberger
IPC: C07D471/04 , A61K31/497 , C07K16/28
Abstract: Provided herein are KRAS G12C inhibitors, such as composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
-
公开(公告)号：US11905281B2
公开(公告)日：2024-02-20
申请号：US17031607
申请日：2020-09-24
Applicant: Amgen Inc.
Inventor： Brian Alan Lanman , Jian Chen , Anthony B. Reed , Victor J. Cee , Longbin Liu , David John Kopecky , Patricia Lopez , Ryan Paul Wurz , Thomas T. Nguyen , Shon Booker , Nobuko Nishimura , Youngsook Shin , Nuria A. Tamayo , John Gordon Allen , Jennifer Rebecca Allen
IPC: C07D471/04 , C07D213/82 , C07D417/04 , A61K38/07 , C07D487/08 , C07D417/12 , C07D513/04 , C07D487/10 , C07D487/04 , C07D401/04 , C07D239/80 , C07D401/14 , C07D237/34 , C07D403/04 , A61K31/496 , A61K31/416 , A61K31/55 , A61K31/454 , A61K31/519 , A61K31/502 , A61K31/517 , A61K31/5025 , A61P35/00 , A61K31/7068 , C07D275/04 , C07D475/00
CPC classification number: C07D417/04 , A61K31/416 , A61K31/454 , A61K31/496 , A61K31/502 , A61K31/5025 , A61K31/517 , A61K31/519 , A61K31/55 , A61K31/7068 , A61K38/07 , A61P35/00 , C07D237/34 , C07D239/80 , C07D275/04 , C07D401/04 , C07D401/14 , C07D403/04 , C07D417/12 , C07D471/04 , C07D475/00 , C07D487/04 , C07D487/08 , C07D487/10 , C07D513/04
Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
-
Patent Agency Ranking
公开(公告)号：US11845760B2
公开(公告)日：2023-12-19
申请号：US17552016
申请日：2021-12-15
Applicant: AMGEN INC.
Inventor： Shon Booker , Matthew Paul Bourbeau , John R. Butler , Sanne Ormholt Schroder Glad , Brian Alan Lanman , Patricia Lopez , Francesco Manoni , Liping H. Pettus , Ian Sarvary , Nuria A. Tamayo , Mikkel Vestergaard , Nicholas Anthony Weires
IPC: C07D471/04 , C07D471/14 , C07D491/04 , C07D491/14 , C07D495/04 , A61K31/4355 , A61K31/436 , A61K31/4365 , A61K31/437 , A61K31/4375 , A61P35/00 , C07D491/06 , C07D471/06 , C07D471/16 , C07D491/16
CPC classification number: C07D491/06 , A61P35/00 , C07D471/06 , C07D471/16 , C07D491/16
Abstract: Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders. Compounds of Formula I have the following structure:
-
公开(公告)号：US11045484B2
公开(公告)日：2021-06-29
申请号：US16402589
申请日：2019-05-03
Applicant: Amgen Inc.
Inventor： Ryan Paul Wurz , Victor J. Cee , Albert Amegadzie , Ning Chen , Brian Alan Lanman , Michael D. Bartberger
IPC: A61K31/675 , A61P35/00 , A61K31/167 , A61K31/553 , C07K16/30 , A61K45/06
Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
-
公开(公告)号：US20180289720A1
公开(公告)日：2018-10-11
申请号：US15938001
申请日：2018-03-28
Applicant: AMGEN INC.
Inventor： Paul E. Harrington , Kate Ashton , Sean P. Brown , Matthew R. Kaller , Todd J. Kohn , Brian Alan Lanman , Kexue Li , Yunxiao Li , Jonathan D. Low , Ana Elena Minatti , Alexander J. Pickrell , Markian M. Stec , Joshua Taygerly
IPC: A61K31/553 , A61P35/00
CPC classification number: A61K31/553 , A61P35/00 , A61P35/02 , C07D498/08
Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
-
公开(公告)号：US08772480B2
公开(公告)日：2014-07-08
申请号：US13681230
申请日：2012-11-19
Applicant: Amgen Inc.
Inventor： Kristin L. Andrews , Yunxin Y. Bo , Shon Booker , Victor J. Cee , Noel D'Angelo , Bradley J. Herberich , Fang-Tsao Hong , Claire L. M. Jackson , Brian Alan Lanman , Hongyu Liao , Longbin Liu , Nobuko Nishimura , Mark H. Norman , Liping H. Pettus , Anthony B. Reed , Adrian Leonard Smith , Seifu Tadesse , Nuria A. Tamayo , Bin Wu , Ryan Wurz , Kevin C. Yang
IPC: C07D401/04 , C07D401/14 , A61K31/444 , A61K31/53 , A61P35/00
CPC classification number: C07D473/00 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14
Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein the variables are as defined herein.
Abstract translation: 本发明涉及式I化合物或其药学上可接受的盐; 使用该化合物治疗疾病或病症如癌症的方法; 和含有这些化合物的药物组合物，其中变量如本文所定义。
-
公开(公告)号：US20250059205A1
公开(公告)日：2025-02-20
申请号：US18696946
申请日：2022-04-28
Applicant: AMGEN INC.
Inventor： Brian Alan Lanman , Ryan Paul Wurz , Wei Zhao , Xiaofen Li , Michael M. Yamano , Yunxiao Li , Ning Chen , Birgitte Weinreich Husemoen , Sebastian Leth-Petersen , Jose M. Medina , Kexue Li , Liping Pettus , Rene Rahimoff , Primali Vasundera Navaratne , Huan Rui , Christopher P. Mohr
IPC: C07D519/00 , A61K31/4995 , A61K31/517 , C07D487/08
Abstract: The present disclosure provides compounds useful for the inhibition of KRAS G12D. The compounds have a general Formula I: (I) wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, cancer.
-
-
-
-
-
-
-
-
-
Search Results
28
records
(took 0.041 seconds)
